期刊文献+

白细胞介素2受体α与Graves病 被引量:3

Interleukin-2 receptor α and Graves' disease
下载PDF
导出
摘要 白细胞介素2受体α(IL-2Rα)是白细胞介素2受体(IL-2R)的α链,属低亲和力IL-2R,它主要参与T淋巴细胞的活化与增殖,在多种自身免疫性疾病中发挥作用。通过对IL-2Rα与Graves病之间关系的研究,进一步探讨Graves病的发病机制,并为本病的诊断与治疗提供新思路。 Interleukin-2 receptor α(IL-2Rα) is α chain of the interleukin-2 receptor(IL-2R) which belongs to low-affinity IL-2R.IL-2Rα participates in the activation and reduplication of T lymphocyte and plays a role in many autoimmune diseases.To further explore the pathogenesis and provide the new idea with the diagnosis and treatment of Graves' disease,we study the relationship between the IL-2Rα and Graves' disease.
出处 《免疫学杂志》 CAS CSCD 北大核心 2012年第1期83-85,92,共4页 Immunological Journal
关键词 GRAVES病 GRAVES眼病 白细胞介素2受体α 可溶性白细胞介素-2受体 CD25 Graves' disease Graves' ophthalmopathy Interleukin-2 receptor α Soluble interleukin-2 receptor CD25
  • 相关文献

参考文献21

  • 1Mariotti S, Caturegli P, Barbesino G, et al. Thyroid function and thyroid autoimmunity independently modulate serum concentration of soluble interleukin 2 (IL-2) receptor (sIL-2R) in thyroid diseases[J]. Clin Endocrinol (Oxf), 1992, 37(5):415-422.
  • 2孟凤苓,苏胜偶,周红,吴文成,黄振国,刘品力.细胞因子与Graves病的关系[J].中华内分泌代谢杂志,2007,23(6):517-518. 被引量:2
  • 3Jiskra J, Antosova M, Limanova Z, et al. The relationship between thyroid function, serum monokine induced by interferon gamma and soluble interleukin-2 receptor in thyroid autoimmune diseases[J]. Clin Exp Immunol, 2009, 156(2):211-216.
  • 4Ugnr-Altun B, Altun A, ArJkan E, etal. Relationships existing between the serum cytokines levels and bone mineral density in women in the premenopausal period affected by Graves' disease with subclinical hyperthyroidism[J]. Endocr Res, 2003, 29(4):389-398,.
  • 5Zwirska-Korczala K, Berdowska A, Jochem J, et al. Influence of thyroxine on serum soluble interleukin-2 receptor alpha levels in thyroid disorders[J]. J Clin Pharm Ther, 2004, 29(2):151-156.
  • 6Balazs C, Farid NR. Soluble interleukin-2 receptor in sera of patients with Graves' disease[J]. J Autoimmun, 1991, 4(4): 681-688.
  • 7Miyauchi S, Matsuura B, Onji M. Increased levels of serum interleukin-18 in Graves' disease[J]. Thyroid, 2000, 10(9): 815-819.
  • 8Paschke R, Schuppert F, Taton M, et al. Intrathyroidal cytokine gene expression profiles in autoimmune thyroiditis [J]. J Endocrinol, 1994;141(2):309-315.
  • 9孟凤苓,郑宝恒,黄振国,刘品力,刘林娜,杨敬慈,南国珍,苏胜偶.Graves病患者外周血中淋巴细胞表型的变化及其意义[J].中华微生物学和免疫学杂志,2003,23(3):213-214. 被引量:2
  • 10Marazuela M , Garc i a-L 6 pez MA, Figueroa-Vega N. Regulatory T cells in human autoimmune thyroid disease[J].J Clin Endocrinol Metab, 2006, 91 (9):3639-3646.

二级参考文献13

  • 1魏枫,王素华,白琳,徐燕,魏翠英,段春兰.甲亢甲减状态对血清三种细胞因子的影响[J].中国医师杂志,2004,6(9):1195-1196. 被引量:3
  • 2Al-Humaidi MA. Serum cytokines levels in Graves' disease. Saudi Med J, 2000,21:639-644.
  • 3Smallridge RC, Tsokos GC, Barman KD, et al. Soluble interleukin-2 receptor is a thyroid hormone-dependent early-response marker in the treatment of thyrotoxicosis. Clin Diagn Lab Immunol, 1997,4:583-586.
  • 4Ugur-Altun B, Altun A, Arikan E, et al. Relationships existing between the serum cytokines levels and bone mineral density in women in the premenopausal period affected by Graves' disease with subclinical hyperthyroidism. Endocr Res, 2003,29:389-398.
  • 5Komorowski J, Jankiewicz J, Robak J, et al. Cytokines serum levels as the markers of thyroid activation in Graves' disease. ImmunoI Lett, 1998,60 : 143-148.
  • 6Siddiqi A, Monson JP, Wood DF, et al. Serum cytokines in thyrotoxicosis. J Clin Endocrinol Metab, 1999,84:435-439.
  • 7Senturk T, Kozaci LD, Kok F, et al. Proinflammatory eytokine levels in hyperthyroidism. Clin Invest Med, 2003,26:58-63.
  • 8Corrales JJ;Lopez A;Ciudad J.Methimazole therapy in Graves′ disease influences the abnormal expression of CD69 (early activation antigen) on T cells[J],1997(3).
  • 9Corrales JJ;Orfao A;Lopez A.Analysis of IL-2 and IL-6 binding to peripheral blood lymphocytes in Graves disease: relationship with disease activity[J],1997.
  • 10Megumi F;Ken O;Kaori S.Usefulness of surface phenotype study of intrathyroidal lymphocyte obtained by fine needle aspirtion cytology in autoimmune thyroid disease and malignant lymphoma of the thyroid[J],1998.

共引文献2

同被引文献25

  • 1中国甲状腺疾病诊治指南——甲状腺功能亢进症[J].中华内科杂志,2007,46(10):876-882. 被引量:835
  • 2Mao XM, Li HQ, Li Q, et al. Prevention of relapse of Graves' disease by treatment with an intrathyroid injection of dexamethasone[J]. J Clin Endocrinol Metab, 2009, 94(12): 4984-4991.
  • 3Hu Y, Tian W, Zhang LL, et al. Function of regulatory T cells improved by dexamethasone in Graves' disease[J]. Eur J Endocrinol, 2012, 166(4): 641-646.
  • 4Sakaguchi S. Naturally arising Foxp3-expressing CD25 + CD4+ regulatory T cells in immunological tolerance to self and non-sell[J]. Nat Immunol, 2005, 6(4): 345-352.
  • 5Mao CM, Wang S, Xiao YC, et al. Impairement of regulatory capacity of CD4+CD25+regulatory T cells medicated by dendritic cell polarization and hyperthyroidism in Graves' disease [J]. J Immunology, 2011, 186(8): 4734-4743.
  • 6Marazuela M, Garcia Lopez MA, Figueroa Vega N, et al. Regulatory T cells in human autoimmune thyroid disease[J]. J Clin Endocrinol Metab, 2006, 91(9): 3639-3646.
  • 7Prado C, Gomez J, Lopez P, et al. Dexamethasone upregulates FOXP3 expression without increasing regulatory activity[J]. Immunobiology, 2011,216(3): 386-392.
  • 8Chen X, Murakami T, Oppenheim JJ, et al. Differential response of murine CD4+CD25+ and CD4+CD25- T cells to dexamethasone-induced cell death[J]. Eur J Immunol, 2004, 34(3): 859-869.
  • 9Suarez A, Lopez P, Gomez J, et al. Enrichment of CD4 + CD25+sh T cell population in patients with systemic lupus erythematosus treated with glucocorticoids [J]. Ann Rheum Dis, 2006, 65(11): 1512-1517.
  • 10Ling Y, Cao X, Yu Z, et al. Circulating dendritic ceils subsets and CD4+Foxp3+ regulatory T cells in adult patients with chronic ITP before and after treatment with high-dose dexamethasome[J]. Eur J Haematol, 2007, 79(4):310-316.

引证文献3

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部